VaxInnate to Present at Cantor Fitzgerald's Inaugural Healthcare Conference
01 juil. 2015 08h00 HE
|
VaxInnate Corporation
Cranbury, NJ, July 1, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology, today announced plans to present a company overview at Cantor...
VaxInnate Appoints Former CDC Division Chief Thomas Monath to Board of Directors
17 juin 2015 08h00 HE
|
VaxInnate Corporation
Cranbury, NJ, June 17, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology platform, today announced the appointment of Thomas P. Monath,...
VaxInnate Advances Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, into Phase 2 Study
03 juin 2015 08h00 HE
|
VaxInnate Corporation
Cranbury, NJ, June 3, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology platform, today announced the
initiation of a double-blind,...
VaxInnate to Present at Needham & Company 14th Annual Healthcare Conference
07 avr. 2015 08h00 HE
|
VaxInnate Corporation
Cranbury, NJ, April 7, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology, today announced plans to present
at the Needham & Company 14th...
VaxInnate Receives Extension of Contract from BARDA for Development of Seasonal and Pandemic Influenza Vaccines
17 févr. 2015 08h00 HE
|
VaxInnate Corporation
Cranbury, NJ, Feb. 17, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology, today announced that it has
executed a contract modification...
VaxInnate Initiates Phase 1b/2 Clinical Trial of Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, in Elderly
08 déc. 2014 08h00 HE
|
VaxInnate Corporation
Cranbury, NJ, Dec. 8, 2014 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology platform, today announced the
initiation of a double-blind,...
VaxInnate Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, Meets Phase 1 Seasonal Influenza Endpoints
11 nov. 2014 08h00 HE
|
VaxInnate Corporation
Cranbury, NJ, Nov. 11, 2014 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering
next-generation vaccine technology, announced today that enrollment
has concluded in the Phase 1...
VaxInnate Updates Plans to Advance Lead Vaccine Candidate, VAX2012Q in Elderly
08 oct. 2014 09h00 HE
|
VaxInnate Corporation
Cranbury, NJ, Oct. 8, 2014 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology platform, provided an update on
clinical development plans for...